Oppenheimer Maintains Outperform on AtriCure, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on AtriCure (NASDAQ:ATRC) and raises the price target from $32 to $36.
October 30, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed its Outperform rating on AtriCure and increased the price target from $32 to $36, indicating a positive outlook.
The increase in price target from $32 to $36 by Oppenheimer suggests a positive outlook for AtriCure, likely boosting investor confidence and potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100